Genetic Evidence for GLP1R Agonists in Non-Ischaemic Heart Failure - PubMed
5 hours ago
- #Mendelian randomization
- #GLP1R agonists
- #Heart failure
- GLP1R agonists show cardiovascular benefits in obesity and diabetes, with recent trials indicating benefits in heart failure with preserved ejection fraction (HFpEF).
- Drug-target Mendelian randomization (MR) was used to assess GLP1R activation, comparing effects of glycaemic control and weight reduction.
- Genetically proxied GLP1R activation was associated with lower risks of overall heart failure (HF), non-ischaemic HF (ni-HF), and ni-HFpEF.
- The protective effects of GLP1R activation were greater than those from glycaemic control alone and comparable to BMI reduction.
- The study supports further evaluation of GLP1R agonism in cardiometabolic HFpEF, aligning with contemporary trial evidence.